Innopharmax, Inc.

Pegatron Corporation

Pharmaceutical Industry Technology and Development Center

Tsh Biopharm Corporation Ltd.

Wei-Hua Hao

Nien-Chih Wang

Chang-Shan Hsu

Tsung-Hsin Lin

Tien-Chu Chang

Yu-Tsai Yang

Jong-Jing Wang

Pei-Jing Hsu

Li-Chien Chang

Shu-Ping Hsueh

Ta-Chien Lu

Shih Min Chen

Shu-Piing Hsueh

The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.

Oral administration of unstable or poorly-absorbed drugs

An anti-counterfeit method for assisting in face recognition includes the following steps: capturing a dynamic image of an object; filtering a plurality of time-varying signals from the dynamic image to obtain a plurality of filter signals; and comparing the filter signals and preset biological information that corresponds to the object, to output a determining result. When the dynamic image of the object is captured, according to this method, at least one region is interest is set in the dynamic image, and each time-varying signal corresponds to a time-varying gray-scale value of at least one pixel of the dynamic image in the region of interest. An anti-counterfeit system is also provided.

Anti-counterfeit method and system for assisting in face recognition

The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.

Metronomic oral gemcitabine for cancer therapy

A remote control method, and a remote control system and a gateway for implementing the method are provided. The method includes receiving, by a remote control device, a plurality of ultra-wideband signals transmitted by a main control device to calculate position data; calculating, by the remote control device, rotation vector data according to detection data of the remote control device; transmitting, by the remote control device, the rotation vector data and the position data to the main control device to allow the main control device to identify an electronic device the remote control device aims at and transmit control information corresponding to the electronic device to the remote control device according to the rotation vector data and the position data; and displaying, by the remote control device, a control interface for controlling the electronic device according to the received control information.

Remote control system, remote control method and gateway

A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.

Controlled release carvedilol formulation

The present invention provides a oral capsule preparation, comprising a capsule prepared from a drug or the alkaline salt thereof, an oily compound or the alkaline salt thereof, an emulsifier and a polycarbon alcohol, together with an enteric coating disposed on the outer layer of the capsule; wherein said emulsifier is a composition of C6-18 organic fatty acid and an organic amine, or the mixture thereof. The invention also provides a method of preparing the oral capsule preparation of the invention.

Growing community of inventors

Taipei, Taiwan

Wei-Hua Hao